Qianggan Extract Improved Nonalcoholic Steatohepatitis by Modulating LncRNA/circRNA Immune CeRNA Networks

Overview

Journal BMC Complement Altern Med

Publisher Biomed Central

Specialty Rehabilitation Medicine

Date 2019 Jul 5

PMID 31269941

Citations 14

Authors

Mingzhe Zhu

Meng Li

Wenjun Zhou

Yang Yang

Fenghua Li

Li Zhang

Guang Ji

Affiliations

Soon will be listed here.

Abstract

Background: The traditional Chinese medicine prescription, Qianggan formula have been confirmed to be effective on non-alcoholic steatohepatitis (NASH), however, the underlying molecular mechanisms remain obscure.

Methods: Thirty-six male C57BL/6 mice were randomly divided into three groups: normal chow diet group; methionine-and-choline-deficient diet (MCD) group, and Qianggan extract (QG) intervention group (0.4 g/kg daily) that fed with MCD. The efficacy of QG was biochemically and histologically evaluated. The expression profiles of messenger ribonucleic acids (mRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) were examined using microarray and verified by RT-qPCR.

Results: QG significantly improved the phenotypic characteristics of NASH, as serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and lactate dehydrogenase (LDH) levels and liver inflammatory cytokines were significantly decreased. By the cutoff of a 1.5-fold change and P < 0.05, 6193 mRNAs, 5692 lncRNAs and 4843 circRNAs were identified as differentially expressed between the MCD and normal groups, and 514 mRNAs, 1182 lncRNAs and 443 circRNAs were identified as differentially expressed between the QG and MCD groups. The intersections (244 mRNAs, 259 lncRNAs and 98 circRNAs) among the three groups were chosen for analysis. Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment revealed that most overlapping mRNAs were related to immune functions such as natural-killer-cell-mediated cytotoxicity, intestinal immune network for IgA production, and T cell receptor signaling pathway. Pathway interactions, protein-protein interactions and molecular complex detection (MCODE) analysis identified numerous immune-related hub genes e.g. natural cytotoxicity triggering receptor 1(Ncr1), C-X-C motif chemokine ligand 9 (Cxcl9), Klra1, and Cd28. Finally, two lncRNAs (Sngh1 and Slc36a3os) and four circRNAs (circ_0009029, circ_0004572, circ_0009212 and circ_0009453) in competing endogenous RNA (ceRNA) networks were constructed by Cytoscape, and immune-related mRNAs (e.g., Cd28, Cd8a, Il15, and Klrk1) were involved in the ceRNA networks.

Conclusions: LncRNA and circRNA-associated immune ceRNA networks might be the targets of QG in alleviating NASH, and our work may provide valuable clues for exploring the mechanisms underlying the effect of QG.

Citing Articles

CXCL9, IL2RB, and SPP1, potential diagnostic biomarkers in the co-morbidity pattern of atherosclerosis and non-alcoholic steatohepatitis.

Wu X, Yuan C, Pan J, Zhou Y, Pan X, Kang J Sci Rep. 2024; 14(1):16364.

PMID: 39013959 PMC: 11252365. DOI: 10.1038/s41598-024-66287-4.

Circular RNAs in non-alcoholic fatty liver disease: Functions and clinical significance.

Zeng Q, Liu C, Ampuero J, Wu D, Jiang W, Zhou L RNA Biol. 2023; 21(1):1-15.

PMID: 38113132 PMC: 10761141. DOI: 10.1080/15476286.2023.2290769.

Traditional Chinese medicines and natural products targeting immune cells in the treatment of metabolic-related fatty liver disease.

Li Z, Ouyang H, Zhu J Front Pharmacol. 2023; 14:1195146.

PMID: 37361209 PMC: 10289001. DOI: 10.3389/fphar.2023.1195146.

A narrative review: CXC chemokines influence immune surveillance in obesity and obesity-related diseases: Type 2 diabetes and nonalcoholic fatty liver disease.

Ullah A, Din A, Ding W, Shi Z, Pervaz S, Shen B Rev Endocr Metab Disord. 2023; 24(4):611-631.

PMID: 37000372 PMC: 10063956. DOI: 10.1007/s11154-023-09800-w.

Integrated strategy of RNA-sequencing and network pharmacology for exploring the protective mechanism of Shen-Shi-Jiang-Zhuo formula in rat with non-alcoholic fatty liver disease.

Xu Z, Wu F, Niu X, Lu X, Li Y, Zhang S Pharm Biol. 2022; 60(1):1819-1838.

PMID: 36124995 PMC: 9518293. DOI: 10.1080/13880209.2022.2106250.

References

Ashburner M, Ball C, Blake J, Botstein D, Butler H, Cherry J . Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000; 25(1):25-9. PMC: 3037419. DOI: 10.1038/75556. View

Wang H, Zhao Y, Xu K . [Clinical and pathological study on effects of Qianggan Capsule combined lamivudine on hepatic fibrosis in patients with chronic hepatitis B]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006; 26(11):978-80. View

Yonekawa C, Nakae H, Zheng Y, Wada H, Tanaka H, Tajimi K . IL-15 levels in patients with acute hepatic failure. Res Commun Mol Pathol Pharmacol. 2007; 115-116:5-14. View

Friedman R, Farh K, Burge C, Bartel D . Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008; 19(1):92-105. PMC: 2612969. DOI: 10.1101/gr.082701.108. View

Kahraman A, Schlattjan M, Kocabayoglu P, Yildiz-Meziletoglu S, Schlensak M, Fingas C . Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis. Hepatology. 2009; 51(1):92-102. DOI: 10.1002/hep.23253. View

Saeki C, Nakano M, Takahashi H, Saito S, Homma S, Tajiri H . Accumulation of functional regulatory T cells in actively inflamed liver in mouse dendritic cell-based autoimmune hepatic inflammation. Clin Immunol. 2010; 135(1):156-66. DOI: 10.1016/j.clim.2009.12.002. View

Li L, Zhang X, Lan Y, Xu L, Zhang X, Wang H . Treatment of non-alcoholic fatty liver disease by Qianggan Capsule. Chin J Integr Med. 2010; 16(1):23-7. DOI: 10.1007/s11655-010-0023-1. View

Tilg H, Moschen A . Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010; 52(5):1836-46. DOI: 10.1002/hep.24001. View

Cazanave S, Mott J, Elmi N, Bronk S, Masuoka H, Charlton M . A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA. J Lipid Res. 2011; 52(8):1517-25. PMC: 3137017. DOI: 10.1194/jlr.M014654. View

10.

Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi P . A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell. 2011; 146(3):353-8. PMC: 3235919. DOI: 10.1016/j.cell.2011.07.014. View

11.

Heymann F, Hammerich L, Storch D, Bartneck M, Huss S, Russeler V . Hepatic macrophage migration and differentiation critical for liver fibrosis is mediated by the chemokine receptor C-C motif chemokine receptor 8 in mice. Hepatology. 2011; 55(3):898-909. PMC: 4533854. DOI: 10.1002/hep.24764. View

12.

Baffy G, Brunt E, Caldwell S . Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012; 56(6):1384-91. DOI: 10.1016/j.jhep.2011.10.027. View

13.

Chalasani N, Younossi Z, Lavine J, Diehl A, Brunt E, Cusi K . The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55(6):2005-23. DOI: 10.1002/hep.25762. View

14.

Szabo G, Bala S . MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013; 10(9):542-52. PMC: 4091636. DOI: 10.1038/nrgastro.2013.87. View

15.

Semba T, Nishimura M, Nishimura S, Ohara O, Ishige T, Ohno S . The FLS (fatty liver Shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis. BMC Gastroenterol. 2013; 13:120. PMC: 3729543. DOI: 10.1186/1471-230X-13-120. View

16.

Takahashi K, Yan I, Haga H, Patel T . Long noncoding RNA in liver diseases. Hepatology. 2014; 60(2):744-53. PMC: 4110118. DOI: 10.1002/hep.27043. View

17.

Papotto P, Marengo E, Sardinha L, Goldberg A, Rizzo L . Immunotherapeutic strategies in autoimmune uveitis. Autoimmun Rev. 2014; 13(9):909-16. PMC: 4181827. DOI: 10.1016/j.autrev.2014.05.003. View

18.

Steinke F, Xue H . From inception to output, Tcf1 and Lef1 safeguard development of T cells and innate immune cells. Immunol Res. 2014; 59(1-3):45-55. DOI: 10.1007/s12026-014-8545-9. View

19.

Czaja A . Review article: chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets. Aliment Pharmacol Ther. 2014; 40(3):261-79. DOI: 10.1111/apt.12825. View

20.

Jadeja R, Devkar R, Nammi S . Herbal medicines for the treatment of nonalcoholic steatohepatitis: current scenario and future prospects. Evid Based Complement Alternat Med. 2014; 2014:648308. PMC: 4060323. DOI: 10.1155/2014/648308. View